Por Cláudia Lobato da Silva (Department of Bioengineering & iBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico).
The robust and scalable cell manufacturing for the cost-effective delivery of safe and potent cell-derived Advanced Therapy Medicinal Products (ATMPs) relies on process engineering tools to understand the impact of cellular features on cell product function and performance, and how do process variables influence the critical quality attributes of the cell product. Mesenchymal stromal cells (MSC) have been widely exploited as potential therapeutic agents for several conditions due to their intrinsic regenerative and immunomodulatory properties, as well as high proliferative capacity ex-vivo, ease of isolation, multilineage differentiation ability and low immunogenicity. Recently, increasing evidence has proposed extracellular vesicles (EVs) as exosomes, as mediators of many of the MSC-associated therapeutic features. In this presentation I expect to demonstrate that bioengineering strategies, namely bioreactor technologies, represent fundamental tools for the robust development of standardized and high-quality MSC-based products.
Transmissão via Zoom.
